Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Shi Z, Shen C, Yu C, et al. Long non-coding RNA LINC00997 silencing inhibits the progression and metastasis of colorectal cancer by sponging miR-512-3p. Bioengineered. 2021;12(1):627–639.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Liao R, Ma QZ, Zhou CY, et al. Identification of biomarkers related to Tumor-Infiltrating Lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer. Bioengineered. 2021;12(1):1676–1688.
   PubMed Web of Science ®Google Scholar
• Li YP, Du XR, Zhang R, et al. Interleukin-18 promotes the antitumor ability of natural killer cells in colorectal cancer via the miR-574-3p/TGF-beta1 axis. Bioengineered. 2021;12(1):763–778.
   PubMed Web of Science ®Google Scholar
• Liu B, Yan X, Hou Z, et al. Impact of Bupivacaine on malignant proliferation, apoptosis and autophagy of human colorectal cancer SW480 cells through regulating NF-kappaB signaling path. Bioengineered. 2021;12(1):2723–2733.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–193.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375(9719):1030–1047.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii1–9.
   PubMed Web of Science ®Google Scholar
• Lee GY, Lee JS, Son CG, et al. Combating drug resistance in colorectal cancer using herbal medicines. Chin J Integr Med. 2020;27(7):551-560.
   Web of Science ®Google Scholar
• Jing C, Ma R, Cao H, et al. Long noncoding RNA and mRNA profiling in cetuximab-resistant colorectal cancer cells by RNA sequencing analysis. Cancer Med. 2019;8(4):1641–1651.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer. JAMA. 2017;317(23):2392–2401.
   PubMed Web of Science ®Google Scholar
• Ditsiou A, Cilibrasi C, Simigdala N, et al. The structure-function relationship of oncogenic LMTK3. Sci Adv. 2020;6(46):eabc3099.
   PubMed Web of Science ®Google Scholar
• Lu L, Yuan X, Zhang Q, et al. LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer. Mol Med Rep. 2017;15(4):2015–2022.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang H, Nguyen VT, et al. LMTK3 represses tumor suppressor-like genes through chromatin remodeling in breast cancer. Cell Rep. 2015;12(5):837–849.
   PubMed Web of Science ®Google Scholar
• Shi H, Wu J, Ji M, et al. Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis. Med Oncol. 2013;30(4):754.
   PubMed Web of Science ®Google Scholar
• Shi H, Li Q, Ji M, et al. Lemur tyrosine kinase-3 is a significant prognostic marker for patients with colorectal cancer. Int J Clin Exp Pathol. 2014;7:1101–1107.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Shah K, Lit LC, et al. LMTK3 confers chemo-resistance in breast cancer. Oncogene. 2018;37(23):3113–3130.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Yao Y, Li X, Cheng L, et al. Circular RNA FAT atypical cadherin 1 (circFAT1)/microRNA-525-5p/spindle and kinetochore-associated complex subunit 1 (SKA1) axis regulates oxaliplatin resistance in breast cancer by activating the notch and Wnt signaling pathway. Bioengineered. 2021;12(1):4032–4043.
   PubMed Web of Science ®Google Scholar
• Wang X, Li T. Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1. Bioengineered. 2021;12(1):44–53.
   PubMed Web of Science ®Google Scholar
• Liu W, Miao Y, Zhang L, et al. MiR-211 protects cerebral ischemia/reperfusion injury by inhibiting cell apoptosis. Bioengineered. 2020;11(1):189–200.
   PubMed Web of Science ®Google Scholar
• Ge C, Zeng B, Li R, et al. Knockdown of STIM1 expression inhibits non-small-cell lung cancer cell proliferation in vitro and in nude mouse xenografts. Bioengineered. 2019;10(1):425–436.
   PubMed Web of Science ®Google Scholar
• Heckler MM, Thakor H, Schafer CC, et al. ERK/MAPK regulates ERRgamma expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer. FEBS J. 2014;281(10):2431–2442.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Liu Y, et al. Anticancer action of Psilostachyin-A in 5-fluorouracil-resistant human liver carcinoma are mediated through autophagy induction, G2/M phase cell cycle arrest and inhibiting extracellular-signal-regulated kinase/mitogen activated protein kinase (ERK/MAPK) signaling pathway. Med Sci Monit. 2019;25:6711–6718.
   PubMed Web of Science ®Google Scholar
• Nie Y, Ding Y, Yang M. GRHL2 upregulation predicts a poor prognosis and promotes the resistance of serous ovarian cancer to cisplatin. Onco Targets Ther. 2020;13:6303–6314.
   PubMed Web of Science ®Google Scholar
• Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Transl Lung Cancer Res. 2012;1:179–193.
   PubMedGoogle Scholar
• Sun H, Ou B, Zhao S, et al. USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway. EBioMedicine. 2019;48:236–247.
   PubMed Web of Science ®Google Scholar
• Ye DM, Ye SC, Yu SQ, et al. Drug-resistance reversal in colorectal cancer cells by destruction of flotillins, the key lipid rafts proteins. Neoplasma. 2019;66(4):576–583.
   PubMed Web of Science ®Google Scholar
• Shen W, Xu T, Chen D, et al. Targeting SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by caspase-7 upregulation. Bioengineered. 2019;10(1):459–468.
   PubMed Web of Science ®Google Scholar
• Han Y, Peng Y, Fu Y, et al. MLH1 deficiency induces cetuximab resistance in colon cancer via Her-2/PI3K/AKT signaling. Adv Sci (Weinh). 2020;7(13):2000112.
   PubMedGoogle Scholar
• Hou Z, Sun L, Xu F, et al. Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer. Cancer Lett. 2020;487:63–73.
   PubMed Web of Science ®Google Scholar
• Tan Z, Gao L, Wang Y, et al. PRSS contributes to cetuximab resistance in colorectal cancer. Sci Adv. 2020;6(1):eaax5576.
   PubMed Web of Science ®Google Scholar
• Rosa R, Marciano R, Malapelle U, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 2013;19(1):138–147.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang H, Lit LC, et al. The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin beta(1). Sci Signal. 2014;7(330):ra58.
   PubMed Web of Science ®Google Scholar
• Klug LR, Bannon AE, Javidi-Sharifi N, et al. LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. Oncogene. 2019;38(8):1200–1210.
   PubMed Web of Science ®Google Scholar
• Zhang K, Chen L, Deng H, et al. Serum lemur tyrosine kinase-3: a novel biomarker for screening primary non-small cell lung cancer and predicting cancer progression. Int J Clin Exp Pathol. 2015;8:629–635.
   PubMed Web of Science ®Google Scholar
• Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):103–119.
   PubMed Web of Science ®Google Scholar
• Yang CY, Wang J, Zhang JQ, et al. Human circular RNA hsa_circRNA_101705 (circTXNDC11) regulates renal cancer progression by regulating MAPK/ERK pathway. Bioengineered. 2021;12(1):4432–4441.
   PubMed Web of Science ®Google Scholar
• Yang K, Li Y, Lian G, et al. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Int J Cancer. 2018;142(11):2323–2334.
   PubMed Web of Science ®Google Scholar
• Wang W, Zou L, Zhou D, et al. Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway. Mol Carcinog. 2016;55(9):1329–1342.
   PubMed Web of Science ®Google Scholar
• Chen Y, Deng G, Fu Y, et al. FOXC2 promotes oxaliplatin resistance by inducing epithelial-mesenchymal transition via MAPK/ERK signaling in colorectal cancer. Onco Targets Ther. 2020;13:1625–1635.
   PubMed Web of Science ®Google Scholar
• Xu T, Wu K, Zhang L, et al. Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4alpha and WNK2 regulation. Cell Oncol (Dordr). 2020;43(2):297–310.
   PubMed Web of Science ®Google Scholar